Body weight, femoral length and <i>Notch3</i> transcripts of 8.5–9 week old male <i>Notch3</i>^{<i>em1Ecan</i>} mutant mice (gray bars) and littermate controls (white bars)... by Ernesto Canalis (516050)

HoxA9-ER directly represses <i>Cebpa</i> gene expression in myeloid cells. by Lei Peng (260321)

Acute exercise decreased plasma insulin and glucose. by Mirian A. Kurauti (3146271)

Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, . by Natalie Davis (8556036)

“…<p>Each plot shows the density for the normalised consumer final power at = 0.75, 0.5, and 0.25, from left to right, as the ratio decreases due to increased resource flow during the simulation. …”

Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

Exposure of HOB to chemotherapeutic agents or rTGF-β1 decreased the expression of CXCL-12 and diminished support of pro-B cell chemotaxis. by Stephanie L. Rellick (182765)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Five compounds significantly decrease MAPK1 phosphorylation in K562 cells. by Pamela Y. Ting (713174)

Effect of SERINC5 antagonism on HIV-1 replication in PBMC cultures. by Dorota Kmiec (5646374)

Effect of specific inhibitors on CYP-mediated CK (50 μM) metabolism in HLMs. by Jian Xiao (253329)

Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center by Shiying Tang (5137418)

“…Patients with incidental PCa had a significantly higher mean age (69.2 vs. 62.2 years, P=0.015). Among the 132 patients with PCa, prostate specific antigen (PSA) analysis was available in 76 patients (57.6%), with a median value of 1.06ng/mL, and 61 (80.3%) patients had a PSA value below 4ng/mL. …”

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects: